Journal of IiMER May 2025 such as Proximity Extension Assay and Luminex Assay, his work aims to detect biomarker profiles that support early disease detection, monitoring, and therapeutic intervention. His team has identified novel proteins that may improve diagnostic precision and provide insights into disease mechanisms. BRMEC14: Large International Study LC-OPTIMIZE At BRMEC14, Professor Fraser will discuss how multiplex technologies can be applied to diagnostic processes and precision medicine. He will present findings from an international study investigating the long-term impact of COVID-19 and its potential overlap with ME/CFS, focusing on the identification of diagnostic and prognostic biomarkers. IIMEC17: Innovative Technologies and Clinical Applications Professor Fraser’s expertise in immunology and infectious diseases is relevant to ME/CFS research, particularly given the role of immune system dysfunction and potential infectious triggers in the condition. His research on systemic inflammation, long COVID, and biomarker discovery will be discussed during the chronic infection and biomarkers Professor Fraser’s clinical background ensures that his research findings have practical clinical relevance. His collaborative approach supports multidisciplinary discussions at BRMEC14, contributing to developments in biomarker research. Nancy Klimas (Nova Southeastern University, USA) BRMEC14: Comparative Analysis of Pre-Pandemic ME/CFS and Long COVID Cohorts: Phenotyping Insights and the Sipavibart Monoclonal Antibody Trial Professor Nancy Klimas is a clinical immunologist whose research focuses on the complex interactions between neuroinflammation, immune dysfunction, and energy metabolism in ME/CFS and related conditions. Her work employs advanced computational modelling to dissect disease mechanisms and identify targeted therapeutic strategies. A key area of her research involves a two-stage treatment approach aimed at reducing neuroinflammation and resetting the hypothalamic-pituitary-adrenal (HPA) axis, which is currently being tested in clinical trials. Her team investigates immune cell function abnormalities, including natural killer cell dysfunction, and explores how these contribute to chronic symptoms and disease progression. She applies multi-omics and phenotyping techniques to characterise patient subgroups, aiming to personalise treatment approaches. At BRMEC14, Professor Klimas will present comparative analyses of clinical and biological data from pre-pandemic ME/CFS and Long COVID cohorts to highlight shared and distinct features. She will also report on the ongoing sipavibart monoclonal antibody trial, evaluating its potential to modulate immune responses and improve outcomes in Long COVID, with implications for ME/CFS treatment strategies. Her research advances understanding of the neuro-immune mechanisms underlying these complex illnesses and supports the development of precision medicine approaches tailored to individual patient profiles. Invest in ME Research Page 19 of 43
21 Publizr Home